Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

被引：485

作者：

Hallberg, Bengt ^{[1
]}

Palmer, Ruth H. ^{[1
]}

机构：

[1] Umea Univ, Dept Mol Biol, S-90187 Umea, Sweden

来源：

NATURE REVIEWS CANCER | 2013年 / 13卷 / 10期

基金：

瑞典研究理事会;

关键词：

ANAPLASTIC LYMPHOMA KINASE; LARGE-CELL LYMPHOMA; INFLAMMATORY MYOFIBROBLASTIC TUMOR; NPM-ALK; LUNG-CANCER; MOLECULAR CHARACTERIZATION; DOWN-REGULATION; TRUNCATED FORM; GROWTH-FACTOR; FUSION GENE;

D O I：

10.1038/nrc3580

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The burgeoning field of anaplastic lymphoma kinase (ALK) in cancer encompasses many cancer types, from very rare cancers to the more prevalent non-small-cell lung cancer (NSCLC). The common activation of ALK has led to the use of the ALK tyrosine kinase inhibitor (TKI) crizotinib in a range of patient populations and to the rapid development of second-generation drugs targeting ALK. In this Review, we discuss our current understanding of ALK function in human cancer and the implications for tumour treatment.

引用

页码：685 / 700

页数：16

共 50 条

[41] PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer
Fearon, Abbie E.
Carter, Edward P.
Clayton, Natasha S.
Wilkes, Edmund H.
Baker, Ann-Marie
Kapitonova, Ekaterina
Bakhouche, Bakhouche A.
Tanner, Yasmine
Wang, Jun
Gadaleta, Emanuela
Chelala, Claude
Moore, Kate M.
Marshall, John F.
Chupin, Juliette
Schmid, Peter
Jones, J. Louise
Lockley, Michelle
Cutillas, Pedro R.
Grose, Richard P.
CELL REPORTS, 2018, 22 (09): : 2469 - 2481
[42] An insight into lung cancer: A comprehensive review exploring anaplastic lymphoma kinase tyrosine kinase inhibitors and mechanisms of resistance
Patcas, Adela
Chis, Ana Florica
Militaru, Claudia Florentina
Bordea, Ioana Roxana
Rajnoveanu, Ruxandra
Coza, Ovidiu Florin
Hanna, Reem
Tiberiu, Tamas
Todea, Doina Adina
BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2022, 22 (01) : 1 - 13
[43] The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update
Lai, Raymond
Ingham, Robert J.
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2013, 4 (02) : 119 - 131
[44] The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability
Lobello, Cosimo
Bikos, Vasilis
Janikova, Andrea
Pospisilova, Sarka
CANCERS, 2018, 10 (03)
[45] ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity
Kimura, Hideki
Nakajima, Takahiro
Takeuchi, Kengo
Soda, Manabu
Mano, Hiroyuki
Iizasa, Toshihiko
Matsui, Yukiko
Yoshino, Mitsuru
Shingyoji, Masato
Itakura, Meiji
Itami, Makiko
Ikebe, Dai
Yokoi, Sana
Kageyama, Hajime
Ohira, Miki
Nakagawara, Akira
LUNG CANCER, 2012, 75 (01) : 66 - 72
[46] Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort
Bedas, Aseel
Peledc, Nir
Rabinovich, Natalie Maimon
Mishaeli, Moshe
Shochat, Tzippy
Zer, Alona
Rotem, Ofer
Allen, Aaron M.
Bar, Jair
Dudnik, Elizabeth
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (05) : 275 - 282
[47] Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
Thompson, Jonathan R.
Menon, Smitha P.
Dy, Grace K.
ADMET AND DMPK, 2016, 4 (03): : 186 - 211
[48] The Alk receptor tyrosine kinase regulates Sparkly, a novel activity regulating neuropeptide precursor in the Drosophila central nervous system
Sukumar, Sanjay Kumar
Antonydhason, Vimala
Molander, Linnea
Sandakly, Jawdat
Kleit, Malak
Umapathy, Ganesh
Mendoza-Garcia, Patricia
Masudi, Tafheem
Schlosser, Andreas
Naessel, Dick R.
Wegener, Christian
Shirinian, Margret
Palmer, Ruth H.
ELIFE, 2024, 12
[49] EGFR: An essential receptor tyrosine kinase-regulator of cancer stem cells
Talukdar, Sarmistha
Emdad, Luni
Das, Swadesh K.
Fisher, Paul B.
RECEPTOR TYROSINE KINASES, 2020, 147 : 161 - 188
[50] Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies
Alexander, Peter B.
Wang, Xiao-Fan
FRONTIERS OF MEDICINE, 2015, 9 (02) : 134 - 138

← 1 2 3 4 5 →